Acknowledgements
The authors thank all of the clinical and technical staff at Osaka City University, Osaka, Japan, for their continuous support. They are grateful to Ms. Hisako Fujii for her assistance with the stratification and allocation steps. Financial disclosures: Kouzi Yamaguti, Yasuhito Nakatomi, and Hirohiko Kuratsune declare that they have no financial, general, or institutional competing interests to disclose. Junzo Nojima, Sanae Fukuda and Yasuyoshi Watanabe received research funds from Kaneka, Inc., whose products were used in this study. Funding source: This study was partly supported by a grant from the Kaneka, Inc. (Tokyo, Japan) and a Health Labour and Welfare Sciences Research Grant (Comprehensive Research on Disability Health and Welfare 15dk0310055h0001), Japan. Capsules containing 50 mg of ubiquinol-10 or placebo were provided by Kaneka, Inc.